<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094234</url>
  </required_header>
  <id_info>
    <org_study_id>8mm-TIPS-ChildA</org_study_id>
    <nct_id>NCT03094234</nct_id>
  </id_info>
  <brief_title>8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis</brief_title>
  <official_title>8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to conduct a prospective randomized trial to compare TIPS with 8mm
      expanded polytetrafluoroethylene(ePTFE)-covered stents and endoscopic variceal ligation plus
      propranolol for the prevention of recurrent esophageal variceal bleeding in patients with
      Child A cirrhosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the prevention of recurrent esophageal variceal bleeding, previous clinical studies and
      meta-analysis show that patients treated with transjugular intrahepatic portosystemic shunt
      (TIPS) have lower rebleeding rates compared with endoscopic therapy. However, TIPS is
      associated with higher rates of portosystemic encephalopathy and does not show survival
      benefit. TIPS with a small-diameter may achieve sufficient portal decompression and reduce
      the incidence of hepatic encephalopathy. The aim of this study was to conduct a prospective
      randomized trial to compare TIPS with 8mm ePTFE-covered stents and endoscopic variceal
      ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2017</start_date>
  <completion_date type="Anticipated">March 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal rebleeding rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIPS dysfunction rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of complications</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>8mm-TIPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVL plus propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>8mm-TIPS</intervention_name>
    <description>Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.</description>
    <arm_group_label>8mm-TIPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic variceal ligation (EVL)</intervention_name>
    <description>Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.</description>
    <arm_group_label>EVL plus propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Appropriate dose of propranolol was administered to the patients.</description>
    <arm_group_label>EVL plus propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cirrhosis Patients who had bled from esophageal varices (≥5days and ≤28days) Child-Pugh A -

        Exclusion Criteria:

        The presence of gastric varices Non-cirrhotic portal hypertension Portal vein thrombosis
        The history of hepatic encephalopathy Total bilirubin ≥51.3 umol/L Previous treatment of
        TIPS or surgery Proven malignancy including hepatocellular carcinoma Contraindications to
        TIPS、EVL or propranolol End-stage renal disease under renal replacement therapy;
        Cardiorespiratory failure Pregnancy or patients not giving informed consent for endoscopic
        procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West china hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xuefeng luo</last_name>
      <phone>02885422311</phone>
      <email>luo_xuefeng@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>luo xuefeng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

